Ruxolitinib plus CHOP for untreated T-follicular helper cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with a specific type of lymphoma called nodal T-follicular helper cell lymphoma (including angioimmunoblastic T-cell lymphoma).
- You haven't had any prior chemotherapy or radiation for this lymphoma.
- You are 18 years or older.
- You have at least one tumor that can be measured (for example, a lymph node over 1.5 cm or an area outside the lymph nodes over 1 cm on a scan).
- Your heart, kidneys, and liver are working well enough, and your blood counts are in a safe range.
- You agree to use effective birth control during treatment and for 4 months after the last dose if that applies to you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding one of two experimental drugs to the standard chemotherapy improves outcomes for people with certain types of peripheral T-cell lymphoma, a rare blood cancer. It aims to see if the combination is safe and effective.
This trial tests a combination of belinostat (a targeted drug) plus either azacitidine or pralatrexate for people with relapsed or refractory T-cell lymphoma. The goal is to find a new treatment option when previous therapies have stopped working.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests a new drug (tucidinostat) added to standard chemotherapy (CHOP) for people newly diagnosed with a specific type of lymphoma called PTCL-TFH. It aims to see if the combination works better than standard treatment alone.
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
Hear when a new Follicular Helper T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.